Абстрактная иллюстрация
Article review 2 April 2026

Экономическое бремя шизофрении: необходимость инвестиций в науку

Eugene Rubin & Charles Zorumski: The Economic Burden of Schizophrenia Demands Large-Scale Research Investment

Eugene Rubin y Charles Zorumski: La carga económica de la esquizofrenia exige inversión científica a gran escala

Schizophrenia is a severe chronic disorder that not only prevents millions of people from leading full lives but also inflicts colossal economic damage on society. A recent study published in JAMA Psychiatry has for the first time comprehensively assessed this burden. Total annual costs due to schizophrenia in the United States have reached a shocking sum of $366.8 billion — equivalent to $119,436 per patient.

Where patients live

The living conditions of people with this diagnosis clearly reflect the complexity of their social adaptation. Statistics show that 68% of patients are able to live independently, while 19% require specialised supported housing. The most marginalised group — estimated at 5% — consists of people who have ended up in prison or among the homeless.

Direct and indirect costs

The economic damage comprises two components. Direct costs are estimated at $75 billion. The largest share goes to healthcare funding (41%) and provision of specialised housing (40%), while the justice system accounts for a further 13% of this figure.

Yet the invisible part of the iceberg is far larger: indirect costs total a colossal $292 billion. The bulk of these are linked to people’s withdrawal from economic activity and the crushing burden placed on their families. In the structure of indirect losses, 34% corresponds to unpaid care provided by relatives, and 20% is tied to deteriorating health among the caregivers themselves. Lost patient wages account for 18%, while premature mortality claims a further 15% of all indirect costs.

Investment in science as the only way forward

Schizophrenia is most often diagnosed in youth and exhausts patients and their families over many decades. Early intervention and existing medications can only partially alleviate symptoms. The only real way to radically reduce these enormous human and financial losses is large-scale investment in fundamental scientific research.

At present, research into the causes of schizophrenia is catastrophically underfunded. Only a deep understanding of the biological mechanisms of this disorder and the development of innovative preventive strategies can free patients from suffering and spare society from the multi-billion-dollar burden.

Eugene Rubin & Charles Zorumski

Psychiatrists and researchers

Eugene Rubin and Charles Zorumski are psychiatrists and researchers who authored a landmark study in JAMA Psychiatry on the economic burden of schizophrenia in the United States.

All author reviews on PsyJournal

Best reviews of the month